Loading…
← CockpitCompetitor Analysis › 688805.SS Ningbo Jansen Superconducting Technologies Co Ltd Class AOpen in the cockpit ↗

Ningbo Jansen Superconducting Technologies Co Ltd Class A688805.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum neutral 41
Mkt cap
$818M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$5.05M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+2.1 pp
WACC 12.1%
Hurdle
+18 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥33.20
1D-2.3%
1W-9.5%
1M-5.2%
3M-17.6%
6M-35.9%
YTD-21.2%
1Yn/a
ATR %4.0%
52w lowhigh54.3% off high

What Ningbo Jansen Superconducting Technologies does

Employees: 626

Ningbo Jansen Superconducting Technologies at a glance

Size Ningbo Jansen Superconducting Technologies (688805.SS) is a China Health Care company (Medical Specialties) with a market value of $818M, the 2544th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥33.20 on 18 Nov 2026.

Performance Over six months the shares fell 35.9%, against -12.6% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 35.6% over the last twelve months (peer median +6.2%); the operating margin is 15.9% (peer median 9.4%).

Valuation It trades at 6.8× enterprise value to sales against a peer median of 3.5× (7th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.1 points above its cost of capital (12.1% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 88688805.SS 61
Six months, rebased to 100: Ningbo Jansen Superconducting Technologies against the median of its 20 peers (local-currency closes).

Ningbo Jansen Superconducting Technologies financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥720MCN¥577MCN¥425MCN¥451MCN¥359M
Revenue growth—+36%-6%+26%—
Gross profitCN¥214MCN¥150MCN¥107MCN¥110MCN¥74.6M
EBITDAn/aCN¥98.7MCN¥71.5MCN¥62.1MCN¥48.6M
Net incomeCN¥108MCN¥75.1MCN¥55.8MCN¥48.7MCN¥34.6M
Free cash flown/aCN¥20.0M-CN¥43.8MCN¥33.1M-CN¥51.0M
Capital expendituren/aCN¥24.0MCN¥23.2MCN¥36.7MCN¥14.3M
Total debtCN¥123MCN¥78.8MCN¥76.6MCN¥105MCN¥59.0M

Quarterly statements and history in the cockpit →

Ningbo Jansen Superconducting Technologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%+10%688068MCAPAMSKIDS09653011876033673600SETL301602BBNX688656MLABCTKB0026581302VREX2190688277688626688805.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Ningbo Jansen Superconducting Technologies is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×5×10×688068MCAPAMSKIDS09653011876033673600SETL301602BBNX688656MLABCTKB0026581302VREX2190688277688626688805.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ningbo Jansen Superconducting Technologies is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%MCAPAMS096530118760336736003016026886560026582190688805.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ningbo Jansen Superconducting Technologies is the large dot.

Ningbo Jansen Superconducting Technologies competitors and peer comparison

How Ningbo Jansen Superconducting Technologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ningbo Jansen Superconducting Technologies against its 20 peers (data as of 18 Nov 2026)
Measure688805.SSPeer medianRank in peer set
1-month return-5.2%-4.8%10th lowest of 21
6-month return-35.9%-12.6%4th lowest of 21
Distance from 52-week high-54.3%-37.6%6th lowest of 21
Revenue growth (TTM)+35.6%+6.2%5th highest of 21
Operating margin15.9%9.4%4th highest of 21
EV / Sales6.8×3.5×7th most expensive of 21
Growth the price implies (Req g, 7 yrs)35.6%6.7%2nd most demanding of 13
Growth delivered (Del g)+17.1%+11.8%4th highest of 13
Hurdle (Req g minus delivered)+18.4 pp-3.7 pp2nd most demanding of 13
ROIC minus cost of capital+2.1 pp-1.9 pp8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%6.8×35.6%+17.1%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%9.6×n/an/a
MedCap MCAP.STSweden$811M-4%+17%15%3.6×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%3.0×20.0%+21.4%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%3.4×n/an/a
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%1.0×-6.4%+6.6%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%0.7×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%1.6×-7.1%+11.3%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%7.7×n/an/a
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%12.0×11.1%+4.6%
Beta Bionics BBNXUnited States$779M+42%+44%-73%4.3×n/an/a
HOB Biotech 688656.SSChina$858M-33%+6%7%13.7×37.6%+12.4%
Mesa Laboratories MLABUnited States$775M+33%+2%10%3.6×21.3%+13.2%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%2.6×n/an/a
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%3.3×16.8%+2.9%
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%3.2×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%1.2×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%3.6×3.8%+105.8%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%21.7×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%7.2×n/an/a

Questions

Which companies are Ningbo Jansen Superconducting Technologies's closest peers?
The cockpit's peer set: Beijing Hotgen Biotech (688068.SS), MedCap (MCAP.ST), Advanced Medical Solutions (AMS.L), OrthoPediatrics (KIDS), Seegene (096530.KS), Cofoe Medical Technology (1187.HK), Cisen Pharmaceutical (603367.SS), Modern Dental (3600.HK).
Is Ningbo Jansen Superconducting Technologies expensive compared with its peers?
On ev / sales it trades at 6.8× against a peer median of 3.5×, 7th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Ningbo Jansen Superconducting Technologies stock performed?
Over six months to 18 Nov 2026 the shares returned -35.9% against -12.6% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.